Biogen Inc. 8-K Report: Key Updates on October 30, 2025

Here's a breakdown of the key information extracted from the provided section of the financial report:

1. Entity Information:

• Company Name: Biogen Inc.
• State of Incorporation: Delaware (DE)
• CIK Number: 0000875045
• Address: 225 Binney Street, Cambridge, MA 02142
• Contact Number: 617-679-2000

2. SEC Filing Details:

• Form Type: 8-K (Current Report)
• Filing Date: October 30, 2025

3. Stock Information:

• Common Stock Par Value: $0.0005
• Stock Symbol: BIIB
• Exchange: NASDAQ

4. Filing Context:

• Period Covered: The report covers a single day, October 30, 2025.

Insights:

• The filing is an 8-K, which typically indicates that the company is disclosing significant events or changes concerning its financial status or operations that shareholders should be aware of.
• The concise nature of the report indicates it is focused on immediate, impactful events rather than a detailed financial performance report.
• The report is filed with the SEC, which suggests compliance with regulatory requirements and transparency for investors.
• The low par value of the common stock may indicate that the company has a high number of shares outstanding, which is common in established companies.

This information is critical for stakeholders assessing Biogen Inc.'s current standing and any significant developments that occurred on the filing date.